Johnson & Johnson Acquires Proteologix for $850 Million
On May 16 Johnson & Johnson (J&J) announced that it acquired Proteologix, Inc. for $850 million. Proteologix is privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases. Proteologix’s portfolio includes PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to enter phase 1 development for moderate to severe atopic dermatitis (AD) and moderate to severe asthma, and PX130, a bispecific antibody targeting IL-13 plus IL-22, which is in preclinical development for moderate to severe AD. J&J is one of the largest global healthcare and pharmaceutical companies with more than 130,000 employees worldwide. Its... Read More »
Arbor Biotechnologies Acquires Serendipity
Arbor Biotechnologies announced on May 8 that it entered into an agreement to acquire Serendipity Biosciences. The financial terms were not disclosed. Serendipity Biosciences is a private biotechnology company focused on the discovery of unique gene editing technologies. Serendipity’s novel editing technologies were discovered in the lab of leading gene editing researcher and Arbor Biotechnologies co-founder, Feng Zhang, of the McGovern Institute for Brain Research at MIT and the Broad Institute of MIT and Harvard. Arbor Biotechnologies is a next-generation gene editing biotechnology company based in Cambridge, Massachusetts. It is focused on discovering and developing... Read More »
Deciphera Pharmaceuticals to be Acquired by Ono Pharmaceutical for $2.4 Billion
Deciphera Pharmaceuticals announced on April 29 that it has entered into a definitive merger agreement with Ono Pharmaceutical Co., Ltd. Ono will acquire all outstanding shares of Deciphera common stock for $25.60 per share in cash through a tender offer followed by a merger of Deciphera with a wholly-owned subsidiary of Ono, for a total equity value of $2.4 billion. Deciphera Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch-control inhibitor for the... Read More »
Vertex Pharmaceuticals Purchases Alpine Immune Sciences $4.9 Billion
Vertex Pharmaceuticals announced that it has agreed to acquire Seattle-based Alpine Immune Sciences for $4.9 billion. Alpine Immune Sciences is a clinical-stage biopharmaceutical company, which is engaged in discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The company’s approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. According to its most recent annual report, the company’s revenue for FY 2023 was approximately $58.9 million, and EBITDA was -$43.3 million. Vertex Pharmaceuticals is an American biopharmaceutical company based in... Read More »
Highbridge Capital Management Acquires Gamida Cell for $70 Million
Highbridge Capital Management, based in New York City, announced on March 27 that it entered into an agreement to acquire Gamida Cell, an Israeli biotechnology company. The agreement will see Highbridge Capital Management convert $75 million of existing unsecured convertible senior notes into equity in Gamida as well as supply $30 million of new capital to Gamida. Gamida Cell is a cell therapy pioneer working to turn cells into powerful therapeutics. Its proprietary nicotinamide technology expands the number of cells while maintaining their intrinsic properties to create potentially curative cell therapy products and candidates for patients with cancer. Gamida entered 2024... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
